 
          
            REFERENCES
          
        
        
          1. Kuerer HM, Sahin AA, Hunt KK, et al. Incidence and impact of documented
        
        
          eradication of breast cancer axillary lymph node metastases before
        
        
          surgery in patients treated with neoadjuvant chemotherapy. Ann Surg.
        
        
          1999; 230:72–8.
        
        
          2. Erdahl LM, Boughey JC. Use of sentinel lymph node biopsy to select patients for
        
        
          local-regional therapy after neoadjuvant chemotherapy. Curr Breast
        
        
          Cancer Rep. 2014; 6:10–6.
        
        
          3. Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of
        
        
          National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and
        
        
          B-27. J Clin Oncol. 2008;26:778–85.
        
        
          4. Hicks M, Macrae ER, Abdel-Rasoul M, et al. Neoadjuvant dual HER2-targeted
        
        
          therapy with lapatinib and trastuzumab improves pathologic complete
        
        
          response in patients with early stage HER2- positive breast cancer: a
        
        
          meta-analysis of randomized prospective clinical trials. Oncologist. 2015;
        
        
          20:337–43.
        
        
          5. Denkert C, von Minckwitz G, Brase JC, et al. Tumor-infiltrating lymphocytes
        
        
          and response to neoadjuvant chemotherapy with or without carboplatin
        
        
          in human epidermal growth factor receptor 2–positive and triple-
        
        
          negative primary breast cancers. J Clin Oncol. 2015; 33:983–91.
        
        
          6. Lips EH, Mukhtar RA, Yau C, et al. Lobular histology and response to
        
        
          neoadjuvant chemotherapy in invasive breast cancer. Breast Cancer Res
        
        
          Treat. 2012; 136:35–43.
        
        
          7.
        
        
          Mamounas, E. P, Anderson SJ,
        
        
          Dignam JJ
        
        
          et al. Predictors of Locoregional
        
        
          Recurrence After Neoadjuvant Chemotherapy: Results From Combined
        
        
          Analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and
        
        
          B-27.
        
        
          J Clin Oncol. 2012  10; 30(32):3960-6.
        
        
          8. Caudle AS, Yu TK, Tucker SL, et al. Local-regional control according to
        
        
          surrogate markers of breast cancer subtypes and response to
        
        
          neoadjuvant chemotherapy in breast cancer patients undergoing breast
        
        
          conserving therapy.
        
        
          13T
        
        
          Breast Cancer Res
        
        
          13T
        
        
          2012;14(3):R83.
        
        
          9.
        
        
          Smith, BD. Using Chemotherapy Response to Personalize Choices Regarding
        
        
          Locoregional Therapy: A New Era in Breast Cancer Treatment? J Cin Oncol
        
        
          2012 ; 30(32): 3913-3915.
        
        
          10. Whelan T, Olivotto IA, Parulekar WR, et al. Regional nodal irradiation in early
        
        
          breast cancer. N Engl J Med 2015; 373;4: 307-316.
        
        
          11.
        
        
          Poortmans P, Colette L, Kirkove C, et al. Internal mammary and medial
        
        
          supraclavicular irradiation in breast cancer. N Engl J Med 2015; 373;4:
        
        
          317-327.